株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品のライフサイクルマネジメント:2010〜2020年

Pharmaceutical Product Lifecycle Management 2010-2020

発行 Visiongain Ltd 商品コード 128365
出版日 ページ情報 英文 137 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
医薬品のライフサイクルマネジメント:2010〜2020年 Pharmaceutical Product Lifecycle Management 2010-2020
出版日: 2010年07月06日 ページ情報: 英文 137 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートは、医薬品のライフサイクルマネジメント戦略について検証し、ライフサイクルマネジメント技術の利点と問題点、2010年〜2020年の医薬品業界の見通しなどをまとめ、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 医薬品ライフサイクルマネジメント:イントロダクション

  • 製品ライフサイクルマネジメント(PLM)とは
  • なぜ医薬品業界にPLMが必要なのか
  • PLMとその他の戦略
  • 医薬品業界に対するPLM案

第3章 医薬品業界:特許期限対策

  • 特許法と医薬品業界
  • ジェネリック薬市場
  • この10年の製薬会社にとっての研究開発パイプラインの課題
  • 法規制
  • 結論

第4章 特許期限を迎える製品のPLM戦略

  • 2010年以降の主要薬剤とその商業的見通し
  • Lipitor (Pfizer)
  • Plavix (Sanofi-Aventis/Bristol-Myers Squibb)
  • Seretide (GlaxoSmithKline)
  • Seroquel (AstraZeneca)
  • Crestor (AstraZeneca)
  • Zyprexa (Eli Lilly)
  • Singulair (Merck)
  • Actos (Takeda Pharmaceuticals)
  • Aricept (Eisai/Pfizer) 他

第5章 PLM活動:2015〜2020年

  • 国別比較

第6章 専門家の見解

  • 新興市場の重要性
  • 新興市場における患者動向
  • 新興市場における薬価と償還
  • 新興市場における医薬品業界戦略
  • 新興市場における知的財産問題
  • 新興市場における成長動向
  • 新興市場における治療分野とその他の機会

第7章 結論

図表

目次

The pharmaceutical industry currently faces marked challenges in its long-standing business model. Product lifecycle management (PLM) is being used to maximise the revenue-generating potential of pharmaceuticals, especially in their maturity, but also earlier on. In our new report - Pharmaceutical Product Lifecycle Management 2010-2020 - we examine the PLM strategies that pharmaceutical companies are using. Those measures range from reformulations, new combinations of drugs and expanded indication ranges, to the use of alliances, licensing, mergers and acquisitions.

In our report we consider the advantages and drawbacks of lifecycle management techniques, as well as approaches such as litigating to protect patents and reducing drug development times. We analyse and discuss conditions within the pharma industry, covering commercial, technological, regulatory and legal aspects. Our study considers where the main opportunities and successes will lie from 2010 onwards. Our research shows that optimised product lifecycle management will be of crucial importance to the pharmaceutical industry from 2010 to 2020. But which techniques will best tackle the decline in revenues and growth prevalent in the sector? Our study tackles such questions, providing the information that you require.

Furthermore, our new report profiles twenty leading drugs that are approaching the ' patent cliff' within the next ten years. For those drugs, we investigate and analyse the lifecycle management strategies that companies are using to maximise commercial life and revenue generation. Those leading products include Lipitor, Plavix, Seretide and Seroquel. By analysing approaches the industry is taking, and evaluating the commercial potential for various PLM methods, we provide incisive analysis of pharma PLM activities for this decade.

Comprehensive analysis of pharmaceutical product lifecycle management

Pharmaceutical Product Lifecycle Management 2010-2020 examines that aspect of the pharmaceutical industry and market through a comprehensive review of information sources. We use primary and secondary research. This report provides forward-looking sales analysis, discussions of commercial and technological developments and analysis of market drivers and restraints, including multiple SWOT analyses. There are wide-ranging tables and figures included, as well as a full interview with an authority on the industry. The result is a comprehensive market- and industry-centred study, with detailed analyses and opinion to benefit your work.

Why you should buy Pharmaceutical Product Lifecycle Management 2010-2020

Our report gives you the following benefits in particular:

  • You will receive a comprehensive analysis of the prospects for product lifecycle management from 2010 to 2020, including predicted corporate directions, sales analyses and other important data
  • You will discover commercial prospects for leading drugs, finding out how companies are protecting their brands through PLM
  • You will find out where the pharmaceutical industry and market are heading - technologically and commercially - from 2010 onwards with regards to PLM
  • You will discover the prospects for leading companies and their market strategies, with comparisons and predictions of where success will lie from 2010 onwards
  • You will identify key industry trends and best practice in PLM
  • You will discover the drivers, restraints, competition and opportunities influencing the various aspects of product lifecycle management for pharmaceuticals.

You can obtain this report today

Nobody with an interest in the global pharmaceutical industry and market should overlook our new study. With patent expiry, R&D bottlenecks and other commercial obstacles, effective product lifecycle management will become even more vital, becoming an integral part of product development. Growing healthcare demands - coupled with technological and therapeutic advances - are drivers of the market. Do you want to harness those opportunities? You can stay ahead by ordering our report today.

Table of Contents

1. Executive Summary

  • 1.1 Monoclonal Antibodies in Cancer Therapy: Market Review
  • 1.2 Aims, Scope and Format of the Report
  • 1.3 Research & Analysis Methods

2. Introduction to Monoclonal Antibodies for Cancer Therapy

  • 2.1 Oncology is the Fifth-Largest Therapeutic Class Worldwide by Total Sales
  • 2.2 The Oncology Market is Growing
  • 2.3 Monoclonal Antibodies
    • 2.3.1 What are Monoclonal Antibodies?
    • 2.3.2 How do Monoclonal Antibody Therapies Work?
  • 2.4 Categories of Monoclonal Antibodies for Therapeutic Use
    • 2.4.1 Murine Antibodies
    • 2.4.2 Chimeric and Humanised Antibodies
    • 2.4.3 Fully Human Antibodies
    • 2.4.4 Immunogenicity
  • 2.5 Current Monoclonal Antibody Cancer Therapies
    • 2.5.1 Avastin
    • 2.5.2 MabThera/Rituxan
    • 2.5.3 Herceptin
    • 2.5.4 Erbitux
    • 2.5.5 Vectibix
    • 2.5.6 Campath
    • 2.5.7 Mylotarg
    • 2.5.8 Zevalin
    • 2.5.9 Bexxar
    • 2.5.10 Arzerra
    • 2.5.11 TheraCIM
    • 2.5.12 Removab

3. Cancer Therapy MAbs: World Market Prospects, 2010-2025

  • 3.1 The Market for Monoclonal Antibodies in Cancer Therapy, 2009
  • 3.2 The Biotech Market is Expanding Rapidly
    • 3.2.1 Monoclonal Antibodies - Leading Class in the Pharma Biotech Market
    • 3.2.2 Oncology is a Major Sales Driver in the Monoclonal Antibodies Market
  • 3.3 Cancer Therapy MAbs: Market Forecast, 2010-2025
  • 3.4 The Big Three Monoclonal Antibodies in Cancer Therapy
  • 3.5 Generic Competition
  • 3.6 Chimeric Antibodies
  • 3.7 The Shift Towards Human Antibodies

4. The Leading Monoclonal Antibodies in Cancer Therapy, 2010-2025

  • 4.1 The Leading Four Monoclonal Antibodies Accounted for 34% of the Global Cancer Drug Market in 2009
  • 4.2 Avastin (Bevacizumab)
    • 4.2.1 Avastin Leads the Market for Monoclonal Antibodies in Cancer Therapy
    • 4.2.2 Avastin Will Show High Growth - But Will it Last?
  • 4.3 MabThera/Rituxan (Rituximab)
    • 4.3.1 MabThera/Rituxan Sales Forecast, 2010-2015
    • 4.3.2 Long-Term Prospects for MabThera/Rituxan, 2015-2025
    • 4.3.3 Competition for MabThera/Rituxan
    • 4.3.4 Biosimilar MabThera/Rituxan
  • 4.4 Herceptin (Trastuzumab)
    • 4.4.1 Short Term Forecast for Herceptin
    • 4.4.2 Long Term Prospects for Herceptin, 2015-2025
    • 4.4.3 Herceptin' s Major Competitors, 2010-2025
  • 4.5 Erbitux (Cetuximab)
    • 4.5.1 Erbitux Sales Forecast, 2010-2015
    • 4.5.2 Erbitux Sales Forecast, 2015-2025
    • 4.5.3 Erbitux' Major Competitors, 2010-2025
  • 4.6 Vectibix (Panitumumab)
    • 4.6.1 Vectibix Sales Forecast, 2010-2025
  • 4.7 Campath (Alemtuzumab)
    • 4.7.1 Campath Sales Forecast, 2010-2025
  • 4.8 Chapter Summary - The Leading Monoclonal Antibodies in Cancer Therapy, 2010-2025

5. SWOT Analysis

  • 5.1 Key Market Drivers
    • 5.1.1 The High Profile of Cancer
    • 5.1.2 The Increasing Prevalence of Cancer
    • 5.1.3 The High Economic Cost of Cancer
    • 5.1.4 Drug Prices
    • 5.1.5 Improvements in Accessibility
    • 5.1.6 Incremental Improvements in Treatment in the Absence of a Complete Cure
    • 5.1.7 New Production Methods Will Reduce Costs
    • 5.1.8 Biologicals versus Chemically-Derived Pharmaceutical Products
    • 5.1.9 Combining Existing Products
    • 5.1.10 Monoclonal Antibodies Have a Lower Risk of Adverse Effects
    • 5.1.11 Promising Pipelines
    • 5.1.12 Personalised Medicine
  • 5.2 Key Market Restraints
    • 5.2.1 High Development Costs
    • 5.2.2 Financial Limitations in Research and Development
    • 5.2.3 Research Bias and ' Me-Too' Drugs
    • 5.2.4 Risk Sharing
    • 5.2.5 Public Health Initiatives
    • 5.2.6 Competition is Fierce for Many Targets
    • 5.2.7 Insufficient Efficacy as Monotherapies
    • 5.2.8 Immunogenicity
    • 5.2.9 Safety Concerns
    • 5.2.10 Mode of Administration is a Limiting Factor
    • 5.2.11 Biosimilar Monoclonal Antibodies

6. Cancer MAbs in the Leading National Pharmaceutical Markets, 2010-2025

  • 6.1 Leading National Markets for Cancer Monoclonal Antibodies, 2009
  • 6.2 National Market Forecasts, 2010-2025
  • 6.3 US Cancer Monoclonal Antibodies Market: Prospects, 2010-2025
  • 6.4 Japanese Cancer Monoclonal Antibodies Market: Prospects, 2010-2025
  • 6.5 Cancer Monoclonal Antibody Markets in the Leading European Countries: Prospects, 2010-2025
  • 6.6 Cancer Monoclonal Antibody Markets in China and India: Prospects, 2010-2025

7. R&D Pipeline for Monoclonal Antibody Cancer Therapies

  • 7.1 New Technology - Monoclonal Antibody Fragments
    • 7.1.1 Bispecific T-Cell Engagers
    • 7.1.2 Tandabs
  • 7.2 Conjugated versus Naked Antibodies
  • 7.3 The Future of Fully Human MAbs
  • 7.4 Competition for Prime Drug Targets
    • 7.4.1 Tailored Medicine
  • 7.5 Late-Stage Pipeline: Additional and Expanded Indications
    • 7.5.1 Avastin
    • 7.5.2 MabThera/Rituxan
    • 7.5.3 Herceptin
    • 7.5.4 Erbitux
  • 7.6 Late-Stage R&D Pipeline Review
    • 7.6.1 Dalotuzumab
    • 7.6.2 Galiximab
    • 7.6.3 Ipilimumab
    • 7.6.4 Ramucirumab
    • 7.6.5 Zalutumumab

8. Expert Opinions

  • 8.1 Dr Mark Cragg
    • 8.1.1 How Do Monoclonal Antibodies Treat Cancer?
    • 8.1.2 The Future of Different Monoclonal Antibody Types
    • 8.1.3 Threats and Limitations
    • 8.1.4 Opportunities
    • 8.1.5 Will Side Effects Limit Growth?
    • 8.1.6 Future Developments
  • 8.2 Dr Janice M. Reichert
    • 8.2.1 Main Challenges
    • 8.2.2 Main Opportunities
    • 8.2.3 Side Effects
    • 8.2.4 Future Developments and Pipelines
    • 8.2.5 The Effect of Biosimilars

9. Conclusions

  • 9.1 The Monoclonal Antibody Market, 2010-2025
  • 9.2 Sales Growth for Monoclonal Antibody Cancer Therapies
  • 9.3 The Monoclonal Antibody R&D Pipeline for Cancer Treatment
  • 9.4 Expansion into Emerging Markets
  • 9.5 Personalised Treatments
  • 9.6 Future Prospects

List of Tables

  • Table 2.1 Monoclonal Antibody Technologies - Overview, 2010
  • Table 2.2 Targets and Indications for Selected FDA-Approved Antibodies, 2010
  • Table 3.1 Monoclonal Antibodies in Cancer Therapy: Overall Sales Forecast, 2010-2016
  • Table 3.2 Monoclonal Antibodies in Cancer Therapy: Overall Sales Forecast, 2017-2025
  • Table 3.3 Leading MAbs in Cancer Therapy: Sales & Market Shares, 2009, 2015, 2020 & 2025
  • Table 3.4 Cancer Monoclonal Antibodies: Sales & Market Shares by Class, 2009
  • Table 4.1 Avastin Sales Forecast, 2010-2016
  • Table 4.2 Avastin Sales Forecast, 2017-2025
  • Table 4.3 MabThera Sales Forecast, 2010-2016
  • Table 4.4 MabThera Sales Forecast, 2017-2025
  • Table 4.5 Herceptin Sales Forecast, 2010-2016
  • Table 4.6 Herceptin Sales Forecast, 2017-2025
  • Table 4.7 Erbitux Sales Forecast, 2010-2016
  • Table 4.8 Erbitux Sales Forecast, 2017-2025
  • Table 4.9 Vectibix Sales Forecast, 2010-2016
  • Table 4.10 Vectibix Sales Forecast, 2017-2025
  • Table 4.11 Campath Sales Forecast, 2010-2016
  • Table 4.12 Campath Sales Forecast, 2017-2025
  • Table 5.1 SWOT Chart for Cancer Monoclonal Antibodies, 2010-2025
  • Table 5.2 Side Effects of Monoclonal Antibody Therapy, 2010
  • Table 5.3 The Importance of Personalised Medicine in Oncology, 2010
  • Table 6.1 Leading National Markets for Cancer MAbs: Sales, 2009
  • Table 6.2 Leading National Markets for Cancer MAbs: Sales Forecasts, 2010-2016
  • Table 6.3 Leading National Markets for Cancer MAbs: Sales Forecasts, 2017-2025
  • Table 6.4 Leading National Markets for Cancer MAbs: Sales & Market Shares, 2009, 2015, 2020 & 2025
  • Table 7.1 Cancer MAb R&D Pipeline: Promising Agents in Phase III, 2010

List of Figures

  • Figure 3.1 Market Shares of the Monoclonal Antibody Therapeutic Areas, 2009
  • Figure 3.2 Sales of the Top Three Monoclonal Antibody Cancer Therapies, 2005-2009
  • Figure 3.3 Monoclonal Antibodies in Cancer Therapy: Overall Sales Forecast, 2010-2025
  • Figure 3.4 Leading MAbs in Cancer Therapy: Market Shares, 2009
  • Figure 3.5 Leading MAbs in Cancer Therapy: Market Shares, 2025
  • Figure 3.6 MAbs in Cancer Therapy: Market Shares by Class, 2009
  • Figure 4.1 Avastin Sales Forecast, 2010-2025
  • Figure 4.2 MabThera Sales Forecast, 2010-2025
  • Figure 4.3 Herceptin Sales Forecast, 2010-2025
  • Figure 4.4 Erbitux Sales Forecast, 2010-2025
  • Figure 4.5 Vectibix Sales Forecast, 2010-2025
  • Figure 4.6 Campath Sales Forecast, 2010-2025
  • Figure 4.7 Leading MAbs in Cancer Therapy: Sales, 2009, 2015 & 2025
  • Figure 4.8 Leading MAbs in Cancer Therapy: Sales Forecasts, 2010-2025
  • Figure 6.1 Leading National Market Shares, 2009
  • Figure 6.2 Leading National Market Shares, 2015
  • Figure 6.3 Leading National Market Shares, 2025
  • Figure 6.4 US: MAbs in Cancer Therapy Sales Forecast, 2010-2025
  • Figure 6.5 Japan: MAbs in Cancer Therapy Sales Forecast, 2010-2025
  • Figure 6.6 Leading European Countries: MAbs in Cancer Therapy Sales Forecasts, 2010-2025
  • Figure 6.7 China & India: MAbs in Cancer Therapy Sales Forecasts, 2010-2025

Companies Listed

  • Abbott
  • Abgenix
  • Affimed
  • American Cancer Society
  • Amgen
  • AstraZeneca
  • Bayer
  • Bayer Schering Pharma
  • Biocon
  • Biogen Idec
  • BioTech Pharma
  • Bristol-Myers Squibb
  • Cell Therapeutics
  • Center of Molecular Immunology [Havana, Cuba]
  • Chugai
  • Corixa (Acquired by GSK)
  • Daiichi-Sankyo
  • Dr. Reddy' s Laboratories
  • Elan Pharmaceuticals
  • Eli Lilly
  • Esteve
  • European Medicines Agency (EMEA)
  • Food and Drug Administration (FDA) [US]
  • Fresenius
  • Genentech
  • Genmab
  • Genzyme
  • GlaxoSmithKline
  • IDEC Pharmaceuticals
  • ILEX Oncology
  • ImClone Systems
  • International Agency for Research on Cancer
  • Johnson & Johnson
  • Lance Armstrong Foundation
  • mAbs
  • Medarex
  • Menarini
  • Merck & Co.
  • Merck KGaA
  • Millennium Pharmaceuticals
  • Morphotek
  • National Health Service (NHS) [UK]
  • National Institute for Health and Clinical Excellence (NICE) [UK]
  • Novartis
  • Oncoscience AG
  • OSI Pharmaceuticals
  • Pfizer
  • Pierre Fabre
  • Roche
  • Southampton General Hospital [UK]
  • Spectrum Pharmaceuticals
  • State Food and Drug Administration (China State FDA)
  • Takeda
  • TeGenero
  • TRION Pharma
  • Tufts University
  • UCB
  • US Food and Drug Administration
  • World Health Organisation (WHO)
  • Wyeth
  • YM Biosciences
  • Zenyaku Kogyo
Back to Top